Irfan Asangani was recently awarded a Department of Defense Idea Expansion Award (2021-2024) for his proposal entitled “PP2A activation as a therapy for AR addicted refractory castration-resistant prostate cancer.” Congratulations Irfan!
Irfan Asangani was recently awarded the Conquer Cancer Now Award 2020-2022 from Concern Foundation for his grant entitled “Towards understanding and targeting transcriptional addiction in advanced prostate cancer.” Read more here – congratulations Irfan!
Irfan Asangani received an NIH R01 grant for research on the Role of MED1 in the AR-dependent transcription in advanced prostate cancer. Congratulations!
Irfan Asanagi received an award from the Sarcoma Foundation of America for the proposal “EWS-FLI1 triggered opportunistic de novo enhancer assembly activates potential cellular therapy targets in Ewing Sarcoma.” Congratulations!
Congratulations to the Wellen, Asangani, and Marmorstein labs for being awarded an AFCRI Discovery Pilot Grant for a collaborative project called “Probing the metabolism-epigenetics link as a therapeutic target in prostate cancer!